PATENT CLAIM ANALYSIS

Application Number: 16108937
Application Type: Utility
Filing Date: 2018-08
Publication Date: 2019-02
Patent Classification: ["514", "480000"]

Abstract:
The present invention provides a method of treating insulin-dependent diabetes mellitus in a subject, comprising administering to the subject a therapeutically effective amount of a Janus kinase inhibitor, or a pharmaceutically acceptable salt or ester thereof, or a therapeutically effective amount of intravenous immunoglobulin, or a therapeutically effective amount of a therapeutic agent that destroys B lymphocytes, or a combination thereof. The present invention also provides kits containing the same.

Claim (Index 16):
The method of  claim 1 , wherein the intravenous immunoglobulin is administered at a dose of 1 to 2 mg per kg weight of the subject every 1 to 3 weeks.

Metadata:
- Claim Count in Document: 50.0
- Percentile: 96.0
- Lexical Diversity: 1.75
- Patent Class: 514.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['14821666', '16013071', '14132549', '15915750', '14211659']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7195618899388792
- 35 USC 102 Novelty (BERT): 0.5060773287239997
- Combined Prediction Score: 0.6982134338173912
- Mean Citation Score: 208.712314
- Max Citation Score: 214.8095
- Similarity Product: 143.28454225841162

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 0
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test